Gestational trophoblastic disease: the significance of vaginal metastases.
Five patients with gestational trophoblastic disease whose presenting symptom was hemorrhage from vaginal metastases have been added to our previous report. The clinical features, management, and responses to treatment are outlined. All the patients required suturing of the bleeding lesions under general anesthetic to arrest the hemorrhage. In addition one patient needed selective arterial embolization. This did not compromise the response to chemotherapy. We confirm our previous view that the presence of vaginal metastases should be classified as a high-risk factor and that these patients be treated with multiple agent chemotherapy from the outset.
D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003475:Curettage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D005260:Female; D006488:Hemostasis, Surgical; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010298:Parity; D011247:Pregnancy; D014328:Trophoblastic Neoplasms / Q000556:secondary* / Q000628:therapy; D014592:Uterine Hemorrhage / Q000209:etiology* / Q000628:therapy; D014594:Uterine Neoplasms / Q000473:pathology*; D014625:Vaginal Neoplasms / Q000556:secondary* / Q000628:therapy
D003609:Dactinomycin; D003520:Cyclophosphamide; D002955:Leucovorin; D008727:Methotrexate